Flecainida [Inn-Spanish]
Flecainida [Inn-Spanish] Brand names, Flecainida [Inn-Spanish] Analogs
Flecainida [Inn-Spanish] Brand Names Mixture
- No information avaliable
Flecainida [Inn-Spanish] Chemical_Formula
C17H20F6N2O3
Flecainida [Inn-Spanish] RX_link
http://www.rxlist.com/cgi/generic2/flecainide.htm
Flecainida [Inn-Spanish] fda sheet
Flecainida [Inn-Spanish] msds (material safety sheet)
Flecainida [Inn-Spanish] Synthesis Reference
No information avaliable
Flecainida [Inn-Spanish] Molecular Weight
414.343 g/mol
Flecainida [Inn-Spanish] Melting Point
No information avaliable
Flecainida [Inn-Spanish] H2O Solubility
48.4 mg/mL at 37oC (acetate form)
Flecainida [Inn-Spanish] State
Solid
Flecainida [Inn-Spanish] LogP
4.06
Flecainida [Inn-Spanish] Dosage Forms
Tablet (50, 100, 150 mg)
Flecainida [Inn-Spanish] Indication
For the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin.
Flecainida [Inn-Spanish] Pharmacology
Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics.
Flecainida [Inn-Spanish] Absorption
Nearly complete following oral administration.
Flecainida [Inn-Spanish] side effects and Toxicity
Oral LD50 is 50-498 mg/kg in rat. Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.
Flecainida [Inn-Spanish] Patient Information
No information avaliable
Flecainida [Inn-Spanish] Organisms Affected
Humans and other mammals
![Flecainida_[Inn-Spanish]](/images/rx/APRD00129.gif)
